Imugene (ASX: IMU) forges development path of immunotherapies and cancer-killing virus (w/ Leslie Chong)

Imugene (ASX: IMU) managing director and chief executive officer Leslie Chong joins Small Caps to discuss the company’s development of its portfolio of immunotherapies, a cancer-killing virus (VAXINIA) and other emerging technologies. Imugene is designing immunotherapies to assist a cancer patient’s immune system in fighting off its malignant cells, while VAXINIA is currently being evaluated in clinical trials. Ms Chong says the company is incredibly eager to unlock the potential of its cancer-killing virus in patients across Australia and the United States where trials are being held. Articles:https://smallcaps.com.au/imugene-patent-pd1-vaxx-immunotherapy-progresses-cancer-killing-virus/ For more information on Imugene:https://smallcaps.com.au/stocks/IMU/See omnystudio.com/listener for privacy information.